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We examined the plasmatic concentrations of quinine in patients with uncomplicated falciparum malaria in an
endemic area of the Amazon region in Brazil in a prospective clinical trial, in which a standard three-day course of
oral quinine plus doxycycline was used. We measured the quinine in the plasma samples on days 0 and 3by high
performance liquid chromatography. The mean concentration of quinine was 6.04 ±2.21 μg/mL in male patients and
5.98 ±1.95 μg/mL in female patients. No significant differences in quinine concentration were observed between
these two groups. All samples collected before starting treatment were negative for quinine. This information could
help in the development of strategies for the rational use of antimalarial drugs in Brazil.
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The monitoring of quinine blood concentration is an
important  approach for better  understanding the
epidemiology of falciparum malaria, especially for a clear
distinction between treatment failure, i.e. the absence of
resolution of clinical signs after antimalarial treatment
associated with inadequate drug concentration, and true
resistance to an antimalarial drug [1,2]. Much work has
been done to determine how blood quinine concentration
profiles correlate with subsequent therapeutic responses
in malaria patients; however, the precise therapeutic range
of plasma quinine levels remains uncertain, because the
pharmacokinetics and the therapeutic response to quinine
varies with drug formulation, patient age and immunity,
the sensibility of the malaria strain [3,4], the fraction bound
to α1-acid-glycoprotein, parasite clearance in the course
of the disease and interracial differences in metabolism
[5]. However, some authors have stated that continuous
concentrations ≥ 6 μg/mL are required to ensure cure [2,4].
There is a lack of knowledge about the plasmatic
concentration of quinine in Brazilian falciparum-malaria
patients that have been treated with the standard three-
day course of oral quinine. We examined the plasmatic
concentrations of quinine in patients with uncomplicated
falciparum malaria in an endemic area of the Amazon region,
in a prospective clinical treatment trial [6].
This study was conducted from January 2006 to
January 2007, on 15 adult male and 15 adult female patients
with uncomplicated P. falciparum malaria admitted to the
public Hospital of Tucurui, Amazonas, Brazil. Patients with
severe or mixed malaria and pregnancy were excluded.
Patients who had taken any antimalarial drugs within the
previous 48 hours were also excluded. All patients were
monitored for at least 28 days within the malaria
transmission area. This study was approved by the ethics
committee of the Tropical Medicine Center of Para Federal
University. Informed consent was obtained from each
subject.
After clinical assessment and disease confirmation
through microscopic examination of blood smears, all
patients were treated with the first line standard three-
day oral treatment regimen of quinine (750 mg), twice a
day, followed by doxycycline hydrochloride (100 mg),
twice a day, for five days and primaquine phosphate
(45mg) on the last day [6]. Reappearance of infection was
assessed in these patients for at least 28 days.
Venous blood samples were taken for quinine level
determination before and on the third day after treatment
began. All blood samples were taken before quinine intake.
The samples (3 mL) were collected in heparinized tubes
and immediately centrifuged at 1500 x for 15 minutes. The
plasma samples were stored at -20 0C until analysis. The
Student’s t test was used to compare the two groups; P<
0.05 was considered significant.
Quinine was analyzed by high performance liquid
chromatography, as described previously [7]. The
analytical procedure validated in our laboratory gave
within-day and day-to-day coefficients of variation of 6.7
and 8.1%, respectively. Mean extraction recovery of the
quinine was 95%. The stability of blank plasma spiked
with quinine was 60 days under the conditions described
above. Primaquine, doxycycline mefloquine, amodiaquine,
acetaminophen and chloroquine do not interfere in the
detection of quinine.
All patients recovered following treatment. The mean
time for parasite clearance was 70.4 hours, varying from
28 to 108 hours. None of the patients had recrudescent
infection, checked until 28 days after treatment.
The mean concentration of quinine in the male plasma
samples in the steady state was 6.04 ± 2.21 μg/mL, ranging
from 3.08 to 10.04 μg/mL; in the female samples it was 5.98
± 1.95 μg/mL, ranging from 2.78 to 9.17 μg/mL. There were
no significant differences between males and females in terms
of quinine concentration in the plasma. These levels were
similar to what was found in other studies, with plasmatic
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quinine concentration during treatment of falciparum
malaria varying from 5.0 to 10.0 μg/mL; they are also
similar to steady state concentrations of quinine in
Afr ican and Asian pat ients  wi th  uncomplicated
falciparum malaria [2,8].
All samples collected before treatment were negative for
quinine and confirmed drug absence. This fact is commonly
observed in the Amazon region; it could favor the development
of resistance of P. falciparum to drugs used in the treatment
of this disease.
Quinine concentrations must remain above levels that
inhibit parasite multiplication throughout the course of
treatment in order to eradicate infection, because there is a
significantly higher probability that a resistant strain will emerge
if the drug is present at suboptimal concentrations. It is very
important to provide an adequate treatment course and to
maintain complete adherence to the prescribed drug regimen in
order to optimize cure rates and reduce the risks of side effects
[1,3,5]. This information could be useful for developing
strategies for the rational use of antimalarial drugs in Brazil.
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